UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF

THE SECURITIES EXCHANGE ACT OF 1934

HEART TEST LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Texas (State of Incorporation or Organization)	26-1344466 (I.R.S. Employer Identification No.)
550 Reserve Street Suite 360 Southlake, Texas	76092
(Address of Principal Executive Offices)	(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of Each Class to be so Registered	Name of Each Exchange on Which Each Class is to be Registered
Common Stock, par value $0.001 per share Warrants to purchase Common Stock	The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement file number to which this form relates: 333-265024

Securities to be registered pursuant to Section 12(g) of the Act:  None.

Item 1: Description of Registrant’s Securities to be Registered

The description of the common stock, par value $0.001 per share (the “Common Stock”), of Heart Test Laboratories, Inc. (the “Company”), to be registered hereunder is contained in the section titled “Description of Securities” in the prospectus forming a part of the Company’s Amendment No. 3 to Registration Statement on Form S-1/A (File No. 333-265024), as filed with the Securities and Exchange Commission on June 13, 2022, as thereafter amended and supplemented from time to time, including any form of prospectus contained therein pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and is incorporated by reference herein.

The description of the warrants to purchase Common Stock (the “Warrants”), of Heart Test Laboratories, Inc., to be registered hereunder is contained in the section titled “Description of Securities—Warrants—Warrants to be Issued in this Offering” in the prospectus forming a part of the Company’s Amendment No. 3 to Registration Statement on Form S-1/A (File No. 333-265024), as filed with the Securities and Exchange Commission on June 13, 2022, as thereafter amended and supplemented from time to time, including any form of prospectus contained therein pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and is incorporated by reference herein.

Item 2: Exhibits

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Company are listed on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

HEART TEST LABORATORIES, INC.
By:	/s/Andrew Simpson
Name:	Andrew Simpson
Title:	Chairman of the Board, President and Chief Executive Officer

Date: June 14, 2022